Drug Profile
Research programme: insulin lispro biosimilar - Wockhardt
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Wockhardt
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 27 Aug 2013 No development reported for Type-1 diabetes mellitus in India (SC)
- 24 Jan 2013 Wockhardt withdraws its plans for a phase III trial in Type 1 diabetes mellitus in USA (NCT01398670)
- 24 Jan 2013 Wockhardt withdraws its plans for three phase I trials in Volunteers in USA (NCT01400802, NCT01399255, NCT01400789)